Mabion S.A. (WSE: MAB)

Market Cap	172.61M
Revenue (ttm)	110.79M
Net Income (ttm)	10.24M
Shares Out	16.16M
EPS (ttm)	0.63
PE Ratio	16.95
Forward PE	21.91
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,831
Open	10.36
Previous Close	10.20
Day's Range	10.34 - 10.80
52-Week Range	10.06 - 23.60
Beta	0.94
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 25, 2024

About Mabion

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. Mabion S.A. was founded in 2007 and is based in Konstantynów Lódzki, Poland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 247
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: MAB

Financial Performance

In 2023, Mabion's revenue was 151.68 million, a decrease of -7.50% compared to the previous year's 163.98 million. Earnings were 41.27 million, an increase of 77.94%.